Peripheral tachykinin receptors as potential therapeutic targets in visceral diseases

Expert Opinion on Therapeutic Targets

Volumn 7, Issue 3, 2003, Pages 343-362

  Lecci, Alessandro ^a   Maggi, Carlo Alberto ^a  

^a Menarini Ricerche SpA   (Italy)

Author keywords

Asthma; Bladder hyperreflexia; Cancer; Cough; Cytotoxicity; HIV; Irritable bowel syndrome (IBS); Nephrotoxicity; Neurokinin A (NKA); Neurokinin B (NKB); NK 1; NK 2; NK 3; Pancreatitis; Pre eclampsia; Substance P (SP); Tachykinin (TK)

Indexed keywords

2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; 3 (2 METHOXY 5 TRIFLUOROMETHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYLPIPERIDINE; ANTINEOPLASTIC AGENT; ANTITUSSIVE AGENT; CP 11974; FK 224; GR 159897; MDL 103392; MEN 11467; N BENZYL N2 [4 HYDROXY 1 [(1 METHYL 1H INDOL 3 YL)CARBONYL]PROLYL] N METHYL 3 (2 NAPHTHYL)ALANINAMIDE; NEPADUTANT; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ 2 RECEPTOR; NEUROKININ 2 RECEPTOR ANTAGONIST; NEUROKININ 3 RECEPTOR; NEUROKININ 3 RECEPTOR ANTAGONIST; NK 5807; NOLPITANTIUM; OSANETANT; SAREDUTANT; SB 235375; SB 235575; SSR 146977; TACHYKININ RECEPTOR; TACHYKININ RECEPTOR ANTAGONIST; TAK 637; TALNETANT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ASTHMA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COUGHING; CYTOTOXICITY; DIARRHEA; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TARGETING; ENTEROPATHY; GASTROINTESTINAL DISEASE; HUMAN; HYPERREFLEXIA; IRRITABLE COLON; NEPHROTOXICITY; NEUROGENIC BLADDER; NONHUMAN; PANCREATITIS; PATHOPHYSIOLOGY; PILOT STUDY; PREECLAMPSIA; RESPIRATORY TRACT DISEASE; REVIEW; UROGENITAL TRACT DISEASE; VISCERA; VOMITING;

ANIMALS; ANTI-ASTHMATIC AGENTS; ANTI-HIV AGENTS; ASTHMA; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; FEMALE; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; GUINEA PIGS; HIV INFECTIONS; HUMANS; MICE; MICE, KNOCKOUT; MUSCLE CONTRACTION; MUSCLE, SMOOTH; PRE-ECLAMPSIA; PREGNANCY; RATS; RECEPTORS, TACHYKININ; TACHYKININS; URINATION DISORDERS;

EID: 0038040876     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.7.3.343     Document Type: Review

References (222)

1. NEUMANN S, DOUBELL TP, LESLIE T, WOOLF CJ: Inflammatory pain hypersensitivity mediated by phenotypic switch in myelinated primary sensory neurons. Nature (1996) 384:360-364.
2. HUNTER DD, MYERS AC, UNDEM BJ: Nerve growth factor-induced phenotypic switch in guinea-pig airway sensory neurons. Am. J. Respir. Crit. Care Med. (2000) 161:1985-1990.
3. MYERS AC, KAJEKAR R, UNDEM BJ: Allergic inflammation-induced neuropeptide production in rapidly adapting afferent nerves in guniea-pig airways. Am. J. Physiol. Lung Mol. Physiol. (2002) 282:L775-L781.
4. CARR MJ, HUNTER DD, JACOBY DB, UNDEM BJ: Expression of tachykinins in non-nociceptive vagal afferent neurons during respiratory viral infection in guinea-pigs. Am. J. Respir. Crit. Care Med. (2002) 165:1071-1075.
5. LECCI A, VALENTI C, MAGGI CA: Tachykinin receptor antagonists in irritable bowel syndrome. Curr. Opin. Invest. Drugs (2002) 3:589-601.
6. PEREZ FONTAN JJ, CORTRIGHT DN, KRAUSE JE et al.: Substance P and neurokinin-1 receptor expression by intrinsic airway neurons in the rat. Am. J. Physiol. Lung. Cell Mol. Physiol. (2000) 278:L344-L355.
7. FREIDIN M, KESSLER JA: Cytokine regulation of substance P expression in sympathetic neurons. Proc. Natl. Acad. Sci. USA (1991) 88:3200-3203.
8. ZIGMOND RE, SUN Y: Regulation of neuropeptide expression in sympathetic neurons. Paracrine and retrograde influences. Ann. NY Acad. Sci. (1997) 814:181-197.
9. MURPHY SM, MATTHEW SE, RODGERS HF, LITURI DT, GIBBINS IL: Synaptic organization of neuropeptide-containing preganglionic boutons in lumbar sympathetic ganglia of guinea-pigs. J. Comp. Neurol. (1998) 398:551-567.
10. SASEK CA, SEYBOLD VS, ELDE RP: The immunohistochemical localization of nine peptides in the sacral parasympathetic nucleus and the dorsal gray commissure in rat spinal cord. Neuroscience (1984) 12:855-873.
11. MAGGI CA: The effects of tachykinins on inflammatory and immune cells. Regul. Pept. (1997) 70:75-90.
12. JOOS GF, DE SWERT KO, PAUWELS RA: Airway inflammation and tachykinins: prospects for the development of tachykinin receptor antagonists. Eur. J. Pharmacol. (2001) 429:239-250.
13. DE GIORGIO R, TAZZARI PL, STANGHELLINI V, CORINALDESI R: Detection of substance P immunoreactivity in human peripheral leukocytes. J. Neuroimmunol. (1998) 82:175-181.
14. ZHANG Y, LU L, FURLONGER C, WU GE, PAIGE CJ: Hemokinin is a hematopoietic-specific tachykinin that regulates B lymphopoiesis. Nat. Immunol. (2000) 1:392-397.
15. SIMON C, PORTALIER P, CHAMOIN MC, TERNAUX JP: Substance P like-immunoreactivity release from enterochromaffin cells of rat caecum. mucosa. Inhibition by serotonin and calcium-free medium. Neurochem. Int. (1992) 20:529-536.
16. CHU HV, KRAFT M, KRAUSE JE, REX MD, MARTIN RJ: Substance P and its receptor neurokinin 1 expression in asthmatic airways. J. Allergy Clin. Immunol. (2000) 106:713-722.
17. PAGE NM,WOODS RJ, LOWRY PJ: A regulatory role for neurokinin B in placental physiology and pre-eclampsia. Regul. Pept. (2001) 98:97-104.
18. PINTO FM, CINTADO CG, DEVILLIER P, CANDENAS ML: Expression of preprotachykinin-B, the gene that encodes neurokinin B, in rat uterus. Eur. J. Pharmacol. (2001) 425:R1-R2.
19. BAE SJ, MATSUNAGA Y, TAKENAKA M et al.: Substance P-induced preprotachykinin-α mRNA, neutral endopeptidase mRNA and substance P in cultured normal fibroblast. Int. Arch. Allergy Immunol. (2002) 127:316-321.
20. D'AGOSTINO B, ADVENIER C, FALCIANI M et al.: Endothelin-1 increases cholinergic nerve-mediated contraction of human bronchi via tachykinin synthesis induction. Br. J. Pharmacol. (2001) 134:1447-1454.
21. MAGHNI K, MICHOUD MC, ALLES M et al.: Airway smooth muscle cells express functional neurokinin-1 receptors and the nerve-derived preprotachykinin-A gene. Am. J. Respir. Cell Mol. Biol. (2003) 28:103-110.
22. FONG TM, ANDERSON SA, YU H, HUANG RR, STRADER. CD: Differential activation of intracellular effector by two isoforms of human neurokinin-1 receptor. Mol. Pharmacol. (1992) 41:24-30.
23. KAGE R, LEEMAN SE, BOYD ND: Biochemical characterization of two different forms of the substance P receptor in rat submaxillary gland. J. Neurochem. (1993) 60:347-351.
24. CANDENAS ML, CINTADO CG, PENNEFATHER JN et al.: Identification of a tachykinin NK2 receptor splice variant and its expression in human and rat tissues. Life Sci. (2002) 72:269-277.
25. PAGE NM, BELL NJ: The human tachykinin NK1 (short form) and tachykinin NK4 receptor: a reappraisal. Eur. J. Pharmacol. (2002) 437:27-30.
26. DERY O, DEFEA KA, BUNNETT NW: Protein kinase C-mediated desensitization of the neurokinin-1 receptor. Am. J Physiol. Cell. Physiol. (2001) 280:C1097-C1106.
27. TRAFTON JA, ABBADIE C, BASBAUM AI: Differential contribution of substance P and neurokinin A to spinal cord neurokinin-1 receptor signaling in the rat. J. Neurosci. (2001) 21:3656-3664.
28. BELLUCCI F, CARINI F, CATALANI C et al.: Pharmacological profile of the novel mammalian tachykinin hemokinin 1. Br. J. Pharmacol. (2002) 135:266-274.
29. RUPNIAK NMJ, KRAMER MS: Discovery of the anti-depressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol. Sci. (1999) 20:485-490.
30. DUFFY RA, VARTY GB, MORGAN CA, LACHOWICZ JE: Correlation of neurokinin (NK)-1 receptor occupancy in gerbil striatum with behavioral effects of NK1 antagonists. J. Pharmacol. Exp. Ther. (2002) 301:536-542.
31. FONG TM, YU H, STRADER CD: Molecular basis for the species selectivity of neurokinin-1 receptor antagonists CP96345 and RP67580. J. Biol. Chem. (1992) 267:25668-25671.
32. JENSEN CJ, GERARD NP, SCHWARTZ TW, GETHER U: The species selectivity of chemically distinct tachykinin nonpeptide antagonists is dependent on common divergent residues of the rat and human neurokinin-1 receptors. Mol. Pharmacol. (1994) 45:294-299.
33. ROGERS DF: Tachykinin receptor antagonists for asthma and COPD. Expert Opin. Ther. Patents (2001) 11:1097-1121.
34. MAZZONE SB, GERAGHTY DP: Respiratory actions of tachykinins in the nucleus of the solitary tract: characterization of receptors using selective agonists and antagonists. Br. J. Pharmacol. (2000) 129:1121-1131.
35. RICCIARDOLO FLM, TREVISANI M, GEPPETTI P, NADEL JA, AMADESI S, BERTRAND C: Role of nitric oxide and septide-insensitive NK1 receptors in bronchoconstriction induced by aereosolized neurokinin A in guinea-pigs. Br. J. Pharmacol. (2000) 129:915-920.
36. NALINE E, MOLIMARD M, REGOLI D, EMONDS-ALT E, BELLAMY JF, ADVENIER C: Evidence for functional tachykinin NK1 receptors on human isolated small bronchi. Am. J. Physiol. (1996) 271:L763-L767.
37. AMADESI S, MOREAU J, TOGNETTO M et al.: NK1 receptor stimulation causes contraction and inositol phosphate increase in medium-size human isolated bronchi. Am. J. Respir. Crit. Care Med. (2001) 163:1026-1211.
38. BARCHASZ E, NALINE E, MOLIMARD, M et al.: Interleukin-1β-induced hyperresponsiveness to Sar9,Met(O2 11-substance P in isolated human bronchi. Eur. J. Pharmacol. (1999) 379:87-95.
39. VAN SCHOOR J, JOOS GF, CHASSON BL, BROUARD RJ, PAUWELS RA: The effect of the NK2 tachykinin receptor antagonist SR 48968 (saredutant) on neurokinin A-induced bronchoconstriction in asthmatics. Eur. Respir. J. (1998) 12:17-23.
40. YU XY, UNDEM BJ, SPANNHAKE EW: Protective effect of substance P on permeability of airway epithelial cells in culture. Am. J. Physiol. (1996) 271:L889-L895.
41. VERONESI B, OORTGIESEN M, CARTER JD, DEVLIN RB: Particulate matter initiates inflammatory cytokine release by activation of capsaicin and acid receptors in a human bronchial epithelial cell line. Toxicol. Appl. Pharmacol. (1999) 154:106-115.
42. HOOD VC, CRUWYS SC, URBAN L, KIDD BL: Differential role of neurokinin receptors in human lymphocyte and monocyte chemotaxis. Regul. Pept. (2000) 96:17-21.
43. BRUNELLESCHI S, NICALI R, LAVAGNO L et al.: Tachykinin activation of human monocytes from patients with interstitial lung disease, healthy smokers, or healthy volunteers. Neuropeptides (2000) 34:45-50.
44. BLUM AM, METWALI A, ELLIOTT DE, WEINSTOCK JV: The T-cell substance P receptor governs antigen-elicited IFN(γ) production. Am. J. Physiol. Gastrointest. Liver Physiol. (2003) 284-G197-G204.
45. HOSHINO H, LOTVALL J, SKOOG B-E, LINDEN A: Neutrophil recruitment by interleukin-17 into rat airways in vivo. Am. J. Respir. Crit. Care Med. (1999) 159:1423-1428.
46. KING KA, RODRIGUEZ MM, ROMAGUERA R, JIANG X, PIEDIMONTE G: Exaggerated neurogenic inflammation and substance P receptor upregulation in RSV-infected weanling rats. Am. J. Respir. Cell. Mol. Biol. (2001) 24:101-107.
47. JACOBY DB, YOST BL, ELWOOD T, FRYER AD: Effects of neurokinin receptor antagonists in virus-infected airways. Am. J. Physiol. Lung Cell. Mol. Physiol. (2000) 279:L59-L65.
48. NAGANO Y, TAMAOKI J, NISHIMURA K, YAMAWAKI I, NAGAI A: Adenosine A3 receptor-mediated airway microvascular leakage: role of mast cells and tachykinins. Res. Commun. Mol. Pathol. Pharmacol. (2000) 108:96-107.
49. BALUK P, BERTRAND C, GEPPETTI P, MCDONALD DM, NADEL JA: NK1 receptor antagonist CP-99994 inhibits cigarette smoke-induced neutrophil and eosinophil adhesion in rat tracheal venules. Exp. Lung Res. (1996) 22:409-418.
50. LIN YS, HO CY, TANG GJ, KOU YR: Alleviation of wood smoke-induced lung injury by tachykinin receptor antagonist and hydroxyl radical scavenger in guniea-pigs. Eur. J. Pharmacol. (2001) 425:141-148.
51. SCHUILING M, ZUIDHOF AB, ZAAGSMA J, MEURS H: Involvement of tachykinin NK1 receptor in the development of allergen-induced airway hyperreactivity and airway inflammation in conscious, unrestrained guinea-pigs. Am. J. Respir. Crit. Care Med. (1999) 159:423-430.
52. HAMAMOTO J, KOHROGI H, KAWANO O et al.: Esophageal stimulation by hydrochloric acid causes neurogenic inflammation in the airways in guinea-pigs. J. Appl. Physiol. (1997) 82:738-745.
53. KOHOROGI H, HAMAMOTO J, KAWANO O et al.: The role of substance P release in the lung with esophageal acid. Am. J. Med. (2001) 111(Suppl. 8A):S25-S30.
54. DAOUI S, D'AGOSTINO B, GALLELLI L, EMONDS-ALT X, ROSSI F, ADVENIER C: Tachykinins and airway microvascular leakage induced by HCl intrao-oesophageal instillation. Eur. Respir. J. (2002) 20-268-273.
55. BOICHOT E, BIYAH K, GERMAIN N, EMONDS-ALT X, LAGENTE V, ADVENIER C: Involvement of tachykinin NK1 and NK2 receptors in substance P-induced microvascular leakage hypersensitivity and airway hyperresponsiveness in guinea-pigs. Eur. Resp. J. (1996) 9:1445-1450.
56. HSU TH, LAI YL, KOU YR: Acetylcholine and tachykinin receptor antagonists attenuate wood smoke-induced bronchoconstriction in guinea-pigs. Eur. J. Pharmacol. (1998) 360:175-183.
57. COSTELLO RW, FRYER AD, BELMONTE KE, JACOBY DB: Effects of tachykinin NK1 receptor antagonists on vagal hyperreactivity and neuronal muscarinic receptor function in antigen-challenged guinea-pigs. Br. J. Pharmacol. (1998) 124:267-276.
58. WU ZX, MAIZE DF Jr, SATTERFIELD BE, FRAZER DG, FEDAN JS, DEY RD: Role of intrinsic airway neurons in ozone-induced airway hyperresponsiveness in ferret trachea. J. Appl. Physiol. (2001) 91:371-378.
59. TERAMOTO S, TANAKA H, KANEKO S, ABE S: Neurokinin-1 receptor antagonist inhibits short-term sulfuric acid-induced airway hyperresponsiveness in sensitized guinea-pigs. Int. Arch. Allergy Immunol. (2000) 121:53-56.
60. TRAMONTANA M, SANTICIOLI P. GIULIANI S et al.: Role of tachykinins in Sephadex-induced airway hyperreactivity and inflammation in guinea-pigs. Eur. J. Pharmacol. (2002) 439:149-158.
61. CURRAN DR, WALSH MT, COSTELLO RW: Interaction between inflammatory cells and nerves. Curr. Opin. Pharmacol. (2002) 2:243-248.
62. ICHINOSE M, MIURA M, YAMAUCHI H et al.: A neurokinin-1 receptor antagonist improves exercise-induced airway narrowing in asthmatic patients. Am. J. Respir. Crit. Care Med. (1996) 153:936-941.
63. FAHY JV, WONG HH, GEPPETTI P et al.: Effect of an NK1 receptor antagonist (CP-99,994) on hypertonic saline-induced bronchoconstriction and cough in asthmatic subjects. Am. J. Respir. Crit. Care Med. (1995) 152:879-884.
64. VAN RENSEN ELJ, HIEMSTRA PS, RABE KF, STERK PJ: Assessment of microvascular leakage via sputum induction. The role of substance P and neurokinin A in patients with asthma. Am. J. Respir. Crit. Care Med. (2002) 165:1275-1279.
65. MAA J, GRADY EF, KIM EH et al.: NK1 receptor desensitization and neutral endopeptidase terminate SP-induced pancreatic plasma extravasation. Am. J. Physiol. Gastrointest. Liver Physiol. (2000) 279:G726-G732.
66. HARRISON NK DAWES KE, KWON OJ, BARNES PJ, LAURENT GJ, CHUNG KF: Effects of neuropeptides on human lung fibroblast proliferation and chemotaxis. Am. J. Physiol. (1995) 268:L278-L283.
67. NOVERAL JP, GRUNSTEIN MM: Tachykinin regulation of airway smooth muscle proliferation. Am. J. Physiol. (1995) 269:L339-L343.
68. YANG CM, HSIAO LD, CHIEN CS, LIN CC, LUO SF, WANG CC: Substance P-induced activation of P42/44 mitogen-activated protein kinase associated with cell proliferation in human tracheal smooth muscle cells. Cell Signal (2002) 14:913-923.
69. SHERWOOD JE, MAUSER PJ, CHAPMAN RW: Bronchoconstrictor and respiratory effects of neurokinin A in dogs. J. Pharmacol. Exp. Ther. (1997) 283:788-793.
70. D'AGOSTINO G, ERBELDING D, KILBINGER H: Tachykinin NK2 receptors facilitate acetylcholine release from guinea-pig isolated trachea. Eur. J. Pharmacol. (2000) 396:29-32.
71. IMASAKI T, KOBAYASHI H, HATAISHI R, HAYASHI I, TOMITA T, MAJIMA M: Nitric oxide is generated in smooth muscle layer by neurokinin A and counteracts constriction in guinea-pig airway. Nitric Oxide (2001) 5:465-474.
72. TRAMONTANA M, PATACCHINI R, GIULIANI S et al.: Characterization of the antibronchoconstrictor activity of MEN11420, a tachykinin NK2 receptor antagonist, in guinea-pigs. Eur. J. Pharmacol. (1998) 352:279-288.
73. RIZZO CA, VALENTINE AF, EGAN RW, KREUTNER W, HEY JA: NK2 receptor mediated contraction in monkey, gainea-pig and human airway smooth muscle. Neuropeptides (1999) 33:27-34.
74. MOUSER PJ, SKEANS S, RITACCO G, FERNANDEZ X, HOUSE A, CHAPMAN RW: Effect of tachykinins on airway function in cynomolgus monkeys. Pulm. Pharmacol. Ther. (2001) 14:121-127.
75. 2-adrenoceptor and glucocorticoid receptors in guinea-pig isolated perfused lung. J. Pharm. Pharmacol. (1998) 50:899-905.
76. SCHUILING M, ZUIDHOF AB, MEURS H, ZAAGSMA J: Role of tachykinin NK2 receptor activation in the allergen-induced late asthmatic reaction, airway hyperreactivity and airway inflammatory cell influx in conscious, unrestrained guinea-pigs. Br. J. Pharmacol. (1999) 127:1030-1038.
77. MAGHNI K, TAHA R, AFIF W, QUTAYBA H, MARTIN JG: Dichotomy between neurokinin receptor actions in modulating allergic airway responses in an animal model of helper T cell Type 2 cytokine-associated inflammation. Am. J. Respir. Crit. Care Med. (2000) 162:1068-1074.
78. TANPO T, NABE T, YASUI K, KAMIKI T, KOHNO S: Participation of neuropeptides in antigen-induced contraction of guinea-pig bronchi via NK2 but not NK1 receptor stimulation. Pharmacology (2000) 60:169-174.
79. WOISIN FE, MATSUMOTO T, DOUGLAS GJ, PAUL W, WHALLEY ET, PAGE CP: Effect of antagonists for NK2 and B2 receptors on antigen-induced airway responses in allergic rabbits. Pulm. Pharmacol. Ther. (2000) 13:13-23.
80. WU ZX, ZHOU D, CHEN G, LEE LY: Airway hyperresponsiveness to cigarette smoke in ovalbumin-sensitized guinea-pigs. Am. J. Respir. Crit. Care Med. (2000) 161:73-80.
81. KWONG K, WU ZX, KASHON ML, KRAINAK KM, WISE PM, LEE LY: Chronic smoking enhances tachykinin synthesis and airway responsiveness in guinea-pigs. Am. J. Respir. Cell. Mol. Biol. (2001) 25:299-305.
82. IIDA M, MATSUMOTO T, ISHIDA K, SAKITAMA K, NISHIKAWA K: The effects of NK5807, a novel NK2 receptor antagonist, on animal model of asthma. Jpn. J. Pharmacol. (2001) 85:P197.
83. D'AGOSTINO B, ADVENIER C, DE PALMA R et al.: The involvement of sensory neuropeptides in rabbits sensitized and challenged to Parietaria judaica. Clin. Exp. Allergy (2002) 32:472-479.
84. TOUSIGNANT C, CHAN CC, GUEVREMONT D et al.: NK2 receptors mediate plasma protein extravasation in guinea-pig lower airways. Br. J. Pharmacol. (1993) 108:383-386.
85. SAVOIE C, TOUSIGNANT C, RODGER IW, CHAN CC: Involvement of NK1 and NK2 receptors in pulmonary responses elicited by non-adrenergic, non-cholinergic vagal stimulation in guinea-pigs. J. Pharm. Pharmacol. (1995) 47:914-920.
86. FU L, KANEKO T, IKEDA H et al.: Tachykinin via tachykinin NK2 receptor activation mediate ozone-induced increase in the permeability of tracheal mucosa in guinea-pigs. Br. J. Pharmacol. (2002) 135:1331-1335.
87. D'ORTHO MP, JARREAU PH, DELACOURT C et al.: Tachykinins induce gelatinase production by guinea-pig alveolar macrophages: involvement of NK2 receptors. Am. J. Physiol. (1995) 269:L631-L636.
88. KRANEVELD AD, NIJKAMP FP, VAN OOSTERHOUT AJ: Role for neurokinin-2 receptor in interleukin-5-induced airway hyperresponsiveness but not eosinophilia in guinea-pigs. Am. J. Respir. Crit. Care Med. (1997) 156:367-374.
89. MAPP CE, MIOTTO D, BRACCIONI F et al.: The distribution of neurokinin-1 and neurokinin-2 receptors in human central airways. Am. J. Respir. Crit. Care Med. (2000) 161:207-215.
90. LILLY CM, HALL AE, RODGER IW, KOBZIK L, HALEY KJ, DRAZEN JM: Substance P-induced histamine release in tracheally perfused guinea-pig lungs. J. Appl. Physiol. (1995) 78:1234-1241.
91. CROSS LG, HEANY LG, ENNIS M: Histamine release from human bronchoalveolar lavage mast cells by neurokinin A. Inflamm. Res. (1997) 46:306-309.
92. FORSYTE P, MCGARVEY LP, HEANEY LG, MACMAHON J, ENNIS M: Sensory neuropeptides induce histamine release from bronchoalveolar lavage cells in both nonasthmatic coughers and cough variant asthmatics. Clin. Exp. Alllergy (2000) 30:225-232.
93. CRIMI N, OLIVIERI R, POLOSA R et al.: Effect of oral terfenadine on bronchoconstrictor response to inhaled neurokinin A and histamine in asthmatic subjects. Eur. Respir. J. (1993) 6:1462-1467.
94. MOORE KA, UNDEM BJ, WEINREICH D: Antigen inhalation unmasks NK2 tachykinin receptor-mediated responses in vagal afferents. Am. J. Respir. Crit. Care Med. (2000) 161:232-236.
95. CORDOBA-RODRIGUEZ R, GOVER TD,WEINREICH D: Are silent NK2 tachykinin receptors on primary vagal afferents really silent? Soc. Neurosci. Abs. (1999) 25:411.
96. KATSUNUMA T, MAK JC, BARNES PJ: Glucocorticoids reduce tachykinin NK2 receptor expression in bovine tracheal smooth muscle. Eur. J. Pharmacol. (1998) 26:99-106.
97. 2-adrenoceptor agonist-induced upregulation of tachykinin expression and function in airway smooth muscle. Am. J. Respir. Cell. Mol. Biol. (1999) 21:409-417.
98. 2-adrenergic and tachykinin NK2 receptors. J. Allergy Clin. Immunol. (2000) 106:S104-S108.
99. VAN SCHOOR J, JOOS GF, PAUWELS RA: Effect of inhaled fluticasone on bronchial responsiveness to neurokinin A in asthma. Eur. Respir. J. (2002) 19:997-1002.
100. JOOS GF, SCHELFHOUT V, VAN DE VELDE V, MAGGI CA, PAUWELS R: The effect of the tachykinin NK2 receptor antagonist MEN11420 (nepadutant) on neurokinin A-induced bronchoconstriction in patients with asthma. Am. J. Respir Crit. Care Med. (2001) 163(Suppl. 5):A628.
101. KRAAN J, VINK-KLOOSTER H, POSTMA DS: The NK2 receptor antagonist SR48968C does not improve adenosine hyperresponsiveness and airway obstruction in allergic asthma. Clin. Exp. Allergy (2001) 31:274-278.
102. ICHINOSE M, NAKAJIMA N, TAKAHASHI T, YAMAUCHI H, INOUE H, TAKISHIMA T: Protection against bradykinin-induced bronchoconstriction in asthmatic patients by neurokinin receptor antagonist. Lancet (1993) 340:1248-1251.
103. JOOS GF, VAN SCHOOR J, KIPS JC, PAUWELS R: The effect of inhaled FK224, a tachykinin NK1 and NK2 receptor antagonist, on neurokinin A-induced bronchoconstriction. Am. J. Respir. Crit. Care Med. (1996) 153:1781-1784.
104. JOOS G, VINCKEN W, LOUIS R, WANG J, SHAW M, PAUWELS R: The effect of DNK333A: a dual tachykinin NK1/NK2 receptor antagonist on neurokinin A-induced bronchoconstriction in patients with asthma. Am. J. Respir. Crit. Care Med. (2001) 163(Suppl. 5):A628.
105. GIRARD V, NALINE E, VILAIN P, EMONDS-ALT X, ADVENIER C: Effects of two tachykinin antagonists, SR48968 and SR140333, on cough induced by citric acid in the unanaesthetized guinea-pig. Eur. Respir. J. (1995) 8:1110-1114.
106. CANNING BJ, UNDEM BJ: Evidence that antidromically stimulated vagal afferents activate inhibitory neurons innervating guinea-pig trachealis. J. Physiol. (1994) 480:613-625.
107. CANNING BJ, FISHER A, UNDEM BJ: Pharmacological analysis of the tachykinin receptors that mediate activation of nonadrenergic, noncholinergic relaxant nerves that innervate guinea-pig trachealis. J. Pharmacol Exp. Ther. (1998) 284:370-377.
108. CANNING BJ, REYNOLDS SM, ANUKU LU, KAJEKAR R, MYERS AC: Endogenous neurokinins facilitate synaptic transmission in guinea-pig airway parasympathetic ganglia. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2002) 283:R320-R330.
109. DAOUI S, NALINE E, LAGENTE V, EMONDS-ALT X, ADVENIER C: Neurokinin B and specific tachykinin NK3 receptor agonists-induced airway hyperresponsiveness in the guinea-pig. Br. J. Pharmacol. (2000) 130:49-56.
110. DAOUI S, COGNON C, NALINE E, EMONDS-ALT X, ADVENIER C: Involvement of tachykinin NK3 receptors in citric acid-induced cough and bronchial responses in guinea-pigs. Am. J. Respir. Crit. Care Med. (1998) 158:42-48.
111. EMONDS-ALT X, PROIETTO V, STEINBERG R et al.: Biochemical and pharmacological activities of SSR 146977, a new potent nonpeptide tachykinin NK3 receptor antagonist. Can. J. Physiol. Pharmacol. (2002) 80:482-488.
112. HAY DWP, GIARDINA GAM, GRISWOLD DE et al.: Nonpeptide tachykinin receptor antagonists. III. SB 235375, a low central nervous system-penetrant, potent and selective neurokinin-3 receptor antagonist, inhibits citric acid-induced cough and airways hyperreactivity in guinea-pigs. J. Pharmacol. Exp. Ther. (2002) 300:314-323.
113. 2-adrenoceptor agonist-induced hyperresponsiveness to neurokinin A in guinea-pig isolated trachea. Life Sci. (2002) 72:307-320.
114. DAOUI S, AHNAOU A, NALINE E, EMONDS-ALT X, LAGENTE V, ADVENIER C: Tachykinin NK3 receptor agonists induced microvascular leakage hypersensitivity in guinea-pig airways. Eur. J. Pharmacol. (2001) 433:199-207.
115. NENAN S, GERMAIN N, LAGENTEV, EMONDS-ALT X, ADVENIER C, BOICHOT E: Inhibition of inflammatory cell recruitment by the tachykinin NK3-receptor antagonist, SR 142801, in a murine model of asthma. Eur. J. Pharmacol. (2001) 421:201-205.
116. PHILLIPS JE, HEY JA, CORBOZ MR: Tachykinin NK3 and NK1 receptor activation elicits secretion from porcine airway submucosal glands. Br. J. Pharmacol. (2003) 138:254-260.
117. DAOUI S, CUI YY, LAGENTE V, EMONDS-ALT X, ADVENIER C: A tachykinin NK3 receptor antagonist, SR 142801 (osanetant), prevents substance P-induced bronchial hyperreactivity in guinea-pigs. Pulm. Pharmacol Ther. (1997) 10:261-270.
118. TAKAHAMA K, FUCHIKAMI J, ISOHAMA Y, KAI H, MIYATA T: Neurokinin A but not neurokinin B and substance P, induces codeine-resistant cough in awake guinea-pigs. Regul. Pept. (1993) 46:236-237.
119. UJIIE Y, SEKIZAWA K, AIKAWA T, SASAKI H: Evidence for substance P as an endogenous substance causing cough in guinea-pigs. Am. Rev. Respir. Dis. (1993) 148:1628-1632.
120. MOREAUX B, NEMMAR A, VINCKE G et al.: Role of substance P and tachykinin receptor antagonists in citric acid-induced cough in pigs. Eur. J. Pharmacol. (2000) 48:305-312.
121. XIANG A, UCHIDA Y, NOMURA A et al.: Effects of airway inflammation on cough response in the guinea-pig. J. Appl. Physiol. (1998) 85:1847-1854.
122. YASUMITSU R, HIRAYAMA Y, IMAI T, MIYAYASU K, HIROI J: Effects of specific tachykinin receptor antagonists on citric acid-induced cough and bronchoconstriction in unanaesdietized guinea-pigs. Eur. J. Pharmacol. (1996) 300:215-219.
123. ADVENIER C, EMONDS-ALT X: Tachykinin receptor antagonists and cough. Pulm. Pharmacol. (1996) 9:329-333.
124. BOLSER DC, DEGENNARO FC, O'REILLY S, MCLEOD RL, HEY JA: Central antitussive activity of the NK1 and NK2 tachykinin receptor antagonists, CP-99,994 and SR 48968, in the guinea-pig and cat. Br. J. Pharmacol. (1997) 121:165-170.
125. HOLZER P, HOLZER-PETSCHE U: Tachykinins in the gut. Part I. Expression, release and motor function. Pharmacol. Ther. (1997) 73:173-217.
126. LECCI A, CARINI F, TRAMONTANA M et al.: Nepadutant pharmacokinetics and dose-effect relationships as tachykinin NK2 receptor antagonist are altered by intestinal inflammation in rodent models. J. Pharmacol. Exp. Ther. (2001) 299:247-254.
127. TOULOUSE M, FIORAMONTI J, MAGGI CA, BUENO L: Role of NK2 receptors in gastric barosensitivity and in experimental ileus in rats. Neurogastroenterol. Mot. (2001) 13:45-53.
128. JONES J, BOORMAN J, CANN P et al.: British society of gastroenterology guidelines for the management of irritable bowel syndrome. Gut (2000) 47(Suppl. 2):S1-S19.
129. DE PONTI F, TONINI M: Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs (2001) 61:317-322.
130. LAIRD JMA, OLIVAR T, ROZA C, DE FELIPE C, HUNT SP, CERVERO F: Deficits in visceral pain and hyperalgesia of mice with a disruption of the tachykinin NK1 receptor gene. Neuroscience (2000) 98:345-352.
131. OKANO S, IKEURA Y, INATOMI N: Effects of tachykinin NK1 receptor antagonists on the viscerosensory response caused by colorectal distension. J. Pharmacol. Exp. Ther. (2002) 300:925-931.
132. LEE OY, MUNAKATA J, NALIBOFF BD, CHANG L, MAYER EA: A double-blind parallel group pilot study of the effects of CJ-11,974 and placebo on perceptual and emotional responses to rectosigmoid distension in IBS patients. Gastroenterology (2000) 118:A846.
133. HESKETH PJ, GRALLA RJ, WEBB RT et al.: Randomized Phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. J. Clin. Oncol. (1999) 17:338-343.
134. FURNESS JB, KUMANO K, LARSSON H, KUNZE WA, VOGALIS F: Sensitization of enteric reflexes in the rat colon in vitro. Auton. Neurosci. (2002) 97:19-25.
135. TOULOUSE M, COELHO AM, FIORAMONTI J, LECCI A, MAGGI CA, BUENO L: Role of tachykinin NK2 receptors in normal and altered rectal sensitivity in rats. Br. J. Pharmacol. (2000) 129:193-199.
136. LAIRD JMA, OLIVAR T, LOPEZ-GARCIA JA, MAGGI CA, CERVERO F: Response of rat spinal neurons to distension of inflamed colon: role of tachykinin NK2 receptors. Neuropharmacology (2001) 40:696-701.
137. BIRDER LA, KISS S, DE GROAT WC, LECCI A, MAGGI CA: Effect of nepadutant, a neurokinin 2 tachykinin receptor antagonist, on immediate-early gene expression after trinitrobenzenesulfonic acid-induced colitis in the rat. J. Pharmacol. Exp. Ther. (2003) 304:272-276.
138. ANTON PM, THEODOROU V, FIORAMONTI J, BUENO L: Chronic low-level administration of diquat increases die nociceptive response to gastric distension in rats: role of mast cells and tachykinin receptor activation. Pain (2001) 92:219-227.
139. MCLEAN PG, PICARD C, GARCIA-VILLAR R, MORÉ J, FIORAMONTI J, BUENO L: Effects of nematode infection on sensitivity to intestinal distension: role of tachykinin NK2 receptors. Eur. J. Pharmacol. (1997) 337:279-282.
140. LORDAL M, NAVALESI G, THEODORSSON E, MAGGI CA, HELLSTROM PM: A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine. Br. J. Pharmacol. (2001) 134:215-223.
141. WANG MJ, XIONG SH, LI ZW: Neurokinin B potentiates ATP-evoked currents in rat DRG neurons. Brain Res. (2001) 923:157-162.
142. CROCI T, EMONDS-ALT X, MANARA L: SR48968 selectively prevents faecal excretion following activation of tachykinin NK2 receptors in rats. J. Pharm. Pharmacol. (1994) 46:383-385.
143. JULIA V, SU X, BUENO L, GEBHART GF: Role of neurokinin 3 receptors on responses to colorectal distension in the rat: electrophysiological and behavioral studies. Gastroenterology (1999) 116:1124-1131.
144. EUTAMENE H, THEODOROU V, FIORAMONTI J, BUENO L: Implication of NK1 and NK2 receptors in rat colonic hypersecretion induced by interleukin 1β: role of nitric oxide. Gastroenterology (1995) 109:483-489.
145. EUTAMENE H, THEODOROU V, FIORAMONTI J, BUENO L: Rectal distension-induced colonic net water secretion in rats involves tachykinins, capsaicin sensory, and vagus nerves. Gastroenterology (1997) 112:1595-1602.
146. CROCI T, LANDI M, EMONDS-ALT X, LE FUR G, MAFFRAND JP, MANARA L: Role of tachykinins in castor oil diarrhoea in rats. Br. J. Pharmacol. (1997) 121:375-380.
147. MORIARTY D, GOLDHILL J, SELVE N, O'DONOGHUE DP, BAIRD AW: Human colonic anti-secretory activity of the potent NK1 antagonist SR140333: assessment of potential anti-diarrhoeal activity in food allergy and inflammatory bowel disease. Br. J. Pharmacol. (2001) 133:1346-1354.
148. TOUGH IR, LEWIS CA, FOZARD J, COX HM: Dual and selective antagonism of neurokinin NK1 and NK2 receptor-mediated responses in human colon mucosa. Naunyn Schmiedebergs Arch. Pharmacol. (2003) 367:104-108.
149. TURVILL JL, CONNOR P, FARTHING JG: Neurokinin 1 and 2 receptors mediate cholera toxin secretion in rat jejunum. Gastroenterology (2000) 119:1037-1044.
150. MENZIES JRW, MCKEE R, CORBETT AD: Differential alterations in tachykinin NK2 receptors in isolated colonic circular smooth muscle in inflammatory bowel disease and idiopathic chronic constipation. Regul. Pept. (2001) 99:151-156.
151. LIU L, SHANG F, MARKUS I, BURCHER E: Roles of substance P receptors in human colon circular muscle: alterations in diverticular disease. J. Pharmacol. Exp. Ther. (2002) 302:627-635.
152. VREES MD, PRICOLO VE, POTENTI FM, CAO W: Abnormal motility in patients with ulcerative colitis: the role of inflammatory cytokines. Arch. Surg. (2002) 137:439-445.
153. GRADY EF, YOSHIMI SK, MAA J et al.: Substance P mediates inflammatory oedema in acute pancreatitis via activation of the neurokinin-1 receptor in rats and mice. Br. J. Pharmacol. (2000) 130:505-512.
154. MAA J, GRADY EF, YOSHIMI SK et al.: Substance P is a determinant of lethality in diet-induced hemorrhagic pancreatitis in mice. Surgery (2000) 128:232-239.
155. BANG R, SASS G, KIEMER AK et al.: Neurokinin-1 receptor antagonists CP96345 and L733060 protect mice from cytokine-mediated liver injury. J. Pharmacol. Exp. Ther. (2003) 305:31-39.
156. FOWLER CJ: Intravesical treatment of overactive bladder. Urology (2000) 55(Suppl. 5A):S60-S64.
157. DASGUPTA P, CHANDIRAMANI VA, BECKETT A, SCARAVILLI F, FOWLER CJ: The effect of intravesical capsaicin on suburothelial innervation in patients with detrusor hyperreflexia. Br. J. Urol. (2000) 85:238-245.
158. SHARKEY KA, WILLIAMS RG, SHULTZBERG M, DOCKRAY GJ: Sensory substance P innervation of the urinary bladder, possible site of action of capsaicin in causing urinary retention in rats. Neuroscience (1983) 10:861-868.
159. WAKABAYASHI Y, TOMOYOSHI T, FUJIMIYA M, ARAI R, MAEDA T: Substance P-containing axon terminals in the mucosa of the human urinary bladder: pre-embedding immunohistochemistry using cryostat sections for electron microscopy. Histochemistry (1993) 100:401-407.
160. AVELINO A, CRUZ F: Peptide immunoreactivity and ultrastructure of rat urinary bladder nerve fibers after topical desensitization by capsaicin and resiniferatoxin. Auton. Neurosci. (2000) 86:37-46.
161. MAGGI CA, SANTICIOLI P, GEPPETTI P et al.: The contribution of capsaicin-sensitive innervation to activation of the spinal vesico-vesical reflex in rats: relationship between substance P levels in the urinary bladder and the sensory-efferent function of capsaicin-sensitive sensory neurons. Brain Res. (1987) 415:1-13.
162. CHENG CL, MA CP, DE GROAT WC: Effect of capsaicin on micturition and associated reflexes in chronic spinal rats. Brain Res. (1995) 678:40-48.
163. SHAKER HS, TU LM, KALFOPOULOS M, HASSOUNA M, DION S, ELHILALI M: Hyperreflexia of the urinary bladder: possible role of the efferent function of the capsaicin sensitive primary afferents. J. Urol. (1998) 160:2232-2239.
164. ABDEL-GAWAD M, DION SB, ELHILALI MM: Evidence of a peripheral role of neurokinins in detrusor hyperreflexia: a further study of selective tachykinin antagonists in chronic spinal injured rats. J. Urol. (2001) 165:1739-1744.
165. ABDEL-KARIM A, BIALECKI R, ELHILALI MM: Effects of M274773, a new tachykinin NK2 receptor antagonist, on bladder function of spinalized rats. Br. J. Urol. Int. (2002) 90(Suppl. 2):P-7.4.25.
166. LECCI A, MAGGI CA: Tachykinins as modulators of the micturition reflex in the central and peripheral nervous system. Regul. Pept. (2001) 101:1-18.
167. CARSTAIRS JR, NIMMO AJ, MORRISON JFB: Autoradiographic characterization of prejunctional neurokinin receptors in the rat bladder. Neuropeptides (1992) 22:13-14.
168. MAGGI CA, GIULIANI S, SANTICIOLI P, ABELLI L, GIACHETTI A: Facilitation of reflex micturition by intravesical administration of [βAla8]-neurokinin A (4-10), a selective NK2 tachykinin receptor agonist. J. Urol. (1991) 145:184-187.
169. ISHIZUKA O, MATTIASSON A, ANDERSSON KE: Tachykinin effects on bladder activity in conscious normal rats. J. Urol. (1995) 154:257-261.
170. 2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins? J. Urol. (1995) 153:2034-2038.
171. LECCI A, TRAMONTANA M, GIULIANI S, CRISCUOLI M, MAGGI CA: Effect of tachykinin NK2 receptor blockade on detrusor hyperreflexia induced by bacterial toxin in rats. J. Urol. (1998) 160:206-209.
172. LECCI A, BIRDER LA, MEINI S et al.: Pharmacological evaluation of the role of cyclooxygenase isoenzymes on the micturition reflex following experimental cystitis. Br. J. Pharmacol. (2000) 130:331-338.
173. ISHIZUKA O, IGAWA Y, MATTIASSON A, ANDERSSON KE: Capsaicin-induced bladder hyperreactivity in normal conscious rats. J. Urol. (1994) 152:525-530.
174. LECCI A, GIULIANI S, TRAMONTANA M, CRISCUOLI M, MAGGI CA: MEN11420, a peptide tachykinin NK2 receptor antagonist, reduces motor responses induced by the intravesical administration of capsaicin in vivo. Naunyn Schmiedebergs Arch. Pharmacol. (1997) 356:182-188.
175. LECCI A, CARINI F, TRAMONTANA M et al.: Urodynamic effects induced by intravesical capsaicin in rats and hamsters. Auton. Neurosci. (2001) 91:37-46.
176. MAGGI CA, GIULIANI S, BALLATI L et al.: In vivo evidence for tachykininergic transmission using a new NK2 receptor selective antagonist. J. Pharmacol. Exp. Ther. (1991b) 257:1172-1178.
177. PIETRA C, BETTELLINI R, HAGAN RM, WARD P, MCELROY A, TRIST DG: Effect of selective antagonists at tachykinin NK1 and NK2 receptors on xylene-induced cystitis in rats. Neuropeptides (1992) 22:52.
178. PANDITA RK, ANDERSSON KE: Intravesical adenosine triphosphate stimulates the micturition reflex in awake, freely moving rats. J. Urol. (2002) 168:1230-1234.
179. BUSHFIELD M, METCALFE M, NAYLOR AM: Activation of micturition reflex by NK2 receptor stimulation in the anaesthetized guinea-pig. Br. J. Pharmacol. (1995) 115:875-882.
180. NIMMO AJ, ANDERSSON PO, MORRISON JFB: Reactive changes in neurokinin receptor density following selective denervations and outlet obstruction of rat bladder. J. Physiol. (1992) 446:524.
181. KIBBLE A, MORRISON JFB: Changes in mechanosensitivity and sensitization of urinary bladder afferents in the anesthetized rat following the administration of the selective NK2 antagonist SR48968. J. Physiol. (1996) 497.P, 18P.
182. MORRISON JFB: The activation of bladder wall afferent nerves. Exp. Physiol. (1999) 84:131-136.
183. IGGO A: Tension receptors in the stomach and the urinary bladder. J. Physiol. (1955) 128:593-607.
184. TRAMONTANA M, CATALIOTO RM, LECCI A, MAGGI CA: Role of prostanoids in the contraction induced by a tachykinin NK2 receptor agonist in the hamster urinary bladder. Naunyn Schmiedebergs Arch. Pharmacol. (2000) 361:452-459.
185. MAGGI CA: Prostanoids as local modulators of reflex micturition. Pharmacol. Res. (1992) 25:13-20.
186. FERGUSON DR, KENNEDY I, BURTON TJ: ATP is released from rabbit urinary bladder epithelial cells by hydrostatic pressure changes - a possible sensory mechanism? J. Physiol. (1997) 505(2):503-511.
187. VLASKOVSKA M, KASALOV L, RONG W et al.: P2X3 knock-out mice reveal a major sensory role for urothelial released ATP. J. Neurosci. (2001) 21:5670-5677.
188. LAZZERI M, BENEFORTI P, SPINELLI M, ZANOLLO A., BARBAGLI G, TURINI D: Intravesical resiniferatoxin for the treatment of hypersensitive disorders: a randomized placebo-controlled study. J. Urol. (2000) 164:676-679.
189. SILVA C, RIBEIRO MJ, CRUZ F: The effect of intravesical resiniferatoxin in patients with idiopathic detrusor instability suggests that involuntary detrusor contractions are triggered by C-fiber input. J. Urol. (2002) 168:575-579.
190. RUGGIERI MR, FILER-MAERTEN S, HIEBLE JP, HAY DW: Role of neurokinin receptors in the behavioral effect of intravesical antigen infusion in guinea-pig bladder. J. Urol. (2000) 164:197-202.
191. KISS S,YOSHIYAMA M, CAO YC et al.: Impaired response to chemical irritation of the urinary tract in mice with disruption of the preprotachykinin gene. Neurosci. Lett. (2001) 313:57-60.
192. RAO JN, DEBELJUK L, BARTKE A: Effects of tachykinins on the secretory activity of rat Sertoli cells in vitro. Endocrinology (1995) 136:1315-1318.
193. KUSHNER L, CHIU PY, BRETTSCHNEIDER N et al.: Urinary substance P concentration correlates with urinary frequency and urgency in interstitial cystitis patients treated with intravesical dimethyl sulfoxide and not intravesical anesthetic cocktail. Urology (2001) 57(Suppl. A):S129.
194. PANG X, MARCHAND J, SANT GR, KREAM RM, THEOHARIDES TC: Increased number of substance P positive nerve fibres in interstitial cystitis. Br. J. Urol. (1995) 75:744-750.
195. SMET PJ, MOORE KH, JONAVICIUS J: Distribution and colocalization of calcitonin gene-related peptide, tachykinins, and vasoactive intestinal peptide in normal and idiopathic unstable human urinary bladder. Lab. Invest. (1997) 77:37-49.
196. PEEKER R, ALDENBERGF, DAHLSTROM A. JOHANSSON SL, LI JY, FALL M: Increased tyrosine hydroxylase immunoreactivity in bladder tissue from patients with classic and nonulcer interstitial cystitis. J. Urol. (2000) 163:1112-1115.
197. CAMPBELL DJ, TENIS N, ROSAMILIA A, CLEMENTS JA, DWYER PL: Urinary levels of substance P and its metabolites are not increased in interstitial cystitis. Br. J. Urol. (2001) 87:35-38.
198. GIULIANI S, PATACCHINI R, BARBANTI G et al.: Characterization of the tachykinin neurokinin-2 receptor in the human urinary bladder by means of selective receptor antagonists and peptidase inhibitors. J. Pharmacol. Exp. Ther. (1993) 267:590-595.
199. ZENG XP, MOORE KH, BURCHER E: Characterization of tachykinin NK2 receptors in human urinary bladder. J. Urol. (1995) 153:1688-1692.
200. SABAN R, SABAN MR, NGUYEN NB et al.: Neurokinin-1 (NK-1) receptor is required in antigen-induced cystitis. Am. J. Pathol. (2000) 156:775-780.
201. PALEA S, CORSI M, ARTIBANI W, OSTARDO E, PIETRA C: Pharmacological characterization of tachykinin NK2 receptors on isolated human urinary bladder, prostatic urethra and prostate. J. Pharmacol. Exp. Ther. (1996) 277:700-705.
202. SABAN R, GERARD NP, SABAN MR, NGUYEN NB, DEBOER DJ, WERSHIL BK: Mast cells mediate substance P-induced bladder inflammation through an NK1 receptor-independent mechanism. Am. J. Physiol. Renal Physiol. (2002) 283:F616-F629.
203. AHLUWALIA A, MAGGI CA, SANTICIOLI P, LECCI A, GIULIANI S: Characterization of the capsaicin-sensitive component of cyclophosphamide-induced inflammation in the rat urinary bladder. Br. J. Pharmacol. (1994) 111:1017-1022.
204. ALFIERI AB, GARDNER C: The NK1 antagonist GR203040 inhibits cyclophosphamide-induced damage in the rat and ferret bladder. Gen. Pharmacol. (1997) 29:245-250.
205. ALFIERI AB, CUBEDDU LX: Nitric oxide and NK1-tachykinin receptors in cyclophosphamide-induced cystitis, in rats. J. Pharmacol. Exp. Ther. (2000) 295:824-829.
206. ALFIERI AB, MALAVE A, CUBEDDU LX: Nitric oxide synthases and cyclophosphamide-induced cystitis in rats. Naunyn Schmiedebergs Arch. Pharmacol. (2001) 363:353-357.
207. AHLUWALIA A, DE FELIPE C, O'BRIEN J, HUNT SP, PERRETTI M: Impaired IL-1β-induced neutrophil accumulation in tachykinin NK1 receptor knockout mice. Br. J. Pharmacol. (1998) 124:1013-1015.
208. ALFIERI AB, CUBEDDU LX: Role of NK1 receptors on cisplatin-induced nephrotoxicity in the rat. Naunyn Schmiedebergs Arch. Pharmacol. (2001) 361:334-338.
209. PAGE NM, WOODS RJ, GARDINER SM et al.: Excessive placental secretion of neurokinin B during the third trimester causes pre-eclampsia. Nature (2000) 405:797-800.
210. ROCCON A, MARCHIONNI D, NISATO D: Study of SR142801, a new potent non-peptide NK3 receptor antagonist on cardiovascular responses in conscious guinea-pigs. Br. J. Pharmacol. (1996) 118:1095-1102.
211. GRANT AD, AKHTAR R, GERARD NP, BRAIN SD: Neurokinin B induces oedema formation in the mouse lung via tachykinin receptor-independent mechanisms. J. Physiol. (2002) 543:1007-1014.
212. LAU AH, CHOW SS, NG YS: Immunologically-induced histamine release from rat peritoneal mast cells is enhanced by low levels of substance P. Eur. J. Pharmacol. (2001) 414:295-303.
213. LAI JP, HO WZ, ZHAN GX, YI Y, COLLMAN RG, DOUGLAS SD: Substance P antagonist (CP-96,345) inhibits HIV replication in human mononuclear phagocytes. Proc. Natl. Acad. Sci. USA (2001) 98:3970-3975.
214. LAI JP, HO WZ, YANG JH, WANG X, SONG L, DOUGLAS SD: A non-peptide substance P antagonist down-regulates SP mRNA expression in human mononuclear phagocytes. J. Neuroimmunol. (2002) 128:101-108.
215. QIAN J, YEHIA G, MOLINA CA et al.: Cloning of human preprotachykinin-I promoter and the role of cyclic adenosine 5′-monophosphate response elements in its expression by IL-1 and stem cell factor. J. Immunol. (2001) 166:2553-2561.
216. SINGH D, JOSHI DD, HAMEED M et al.: Increased expression of preprotachykinin-I and neurokinin receptors in human breast cancer cells: implications for bone marrow metastasis. Proc. Natl. Acad. Sci. USA (2001) 97:388-393.
217. GOTO T, TANAKA T. Tachykinins and tachykinin receptors in bone. Microscopy Res. Tech. (2002) 58:91-97.
218. KATAYAMA I, BAE SJ, HAMASAKI Y et al.: Stress response, tachykinin, and cutaneous inflammation. J. Investig. Dermatol. Symp. Proc. (2001) 6:81-86.
219. SCHOLZEN T, ARMSTRONG CA, BUNNETT NW et al.: Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune system. Exp. Dermatol. (1998) 7:81-96.
220. TAI CF, BARANIUK JN: Upper airway neurogenic mechanisms. Curr. Opin. Allergy Clin. Immunol. (2002) 2:11-19.
221. BERTRAND C, GEPPETTI P: Tachykinin and kinin receptor antagonists: therapeutic perspectives in allergy airway disease. Trends Pharmacol Sci. (1996) 17:255-259.
222. COLLINS SM: The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders. Gastroenterology (1996) 111:1683-1699.